Compare Cytokinetics Inc (CYTK) vs Lam Research Corporation (LRCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Lam Research Corporation — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Lam Research Corporation trades at $318.84 (market cap $401.19B). The key difference: Lam Research Corporation is far larger — about 46.5× Cytokinetics Inc's market cap, and Lam Research Corporation pays a 0.41% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Lam Research Corporation for 60 Days on average.
| CYTK | LRCX | |
|---|---|---|
Market Cap | $8.62B | $401.19B |
Volume | 2,594,626 | 8,960,892 |
Sector | Health | Technology |
52-Week High | $87.26 | $433.33 |
52-Week Low | $54.76 | $131.37 |
Typical Hold Time | 19 Days | 60 Days |
Enterprise Value | $8.72B | $399.35B |
Dividend Yield | — | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of -$1.50, beating expectations, but maintains deeply negative profitability with a net income margin of -1,321.12% for 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy studies and presentations at major medical conferences.
Wall Street sentiment is overwhelmingly bullish with a 97.14% buy rating and a $112.60 consensus price target, signaling strong upside potential. However, high cash burn, substantial losses, and significant debt-to-asset ratio of 81.23% present substantial financial risks. Investment appeal hinges on successful commercialization of its pipeline amid intense competition.
Lam Research (LRCX) trades at $320.59, down 2.71% on the day, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $2.18. Revenue grew to $18.44B in 2025, with a net income margin of 31.27%, while valuation ratios like P/E of 55.66 and P/S of 17.4 reflect high growth expectations. Analyst consensus is strongly bullish with a $375.68 price target, supported by AI-driven demand for semiconductor equipment.
The outlook for LRCX is positive due to robust earnings growth and strategic positioning in AI infrastructure, though risks include high valuation multiples and semiconductor cycle volatility. Upside potential exists if the company meets Q3 2026 earnings expectations and maintains margin expansion, but investors should monitor competitive pressures and macroeconomic factors affecting tech spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Lam Research Corporation
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →
